Single-cell RNA-seq recognized the initiator of epithelial ovarian cancer recurrence

被引:0
作者
Tongtong Kan
Shupeng Zhang
Shengtao Zhou
Ya Zhang
Yun Zhao
Yinghua Gao
Tao Zhang
Feng Gao
Xin Wang
Linjie Zhao
Mengsu Yang
机构
[1] City University of Hong Kong,Department of Biomedical Sciences
[2] Beijing Institute of Basic Medical Sciences,Department of Pathology
[3] The Second Affiliated Hospital of Shandong First Medical University,Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second Hospital and State Key Labor
[4] West China Hospital,Department of Pathology
[5] Sichuan University,Department of Biostatistics, School of Public Health
[6] Taian Tumor Prevention and Treatment Hospital,Key Laboratory of Biochip Technology, Shenzhen Research Institute
[7] Shandong University,undefined
[8] City University of Hong Kong,undefined
来源
Oncogene | 2022年 / 41卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Epithelial ovarian cancers (EOCs) are sensitive to chemotherapy but will ultimately relapse and develop drug resistance. The origin of EOC recurrence has been elusive due to intra-tumor heterogeneity. Here we performed single-cell RNA sequencing (scRNA-seq) in 13,369 cells from primary, untreated peritoneal metastasis, and relapse tumors. We used time-resolved analysis to chart the developmental sequence of cells from the metastatic tumors, then traced the earliest replanting cells back to the primary tumors. We discovered seven distinct subpopulations in primary tumors where the CYR61+ “stress” subpopulation was identified as the relapse-initiators. Furthermore, a subpopulation of RGS5+ cancer-associated fibroblasts (CAFs) was found to strongly support tumor metastasis. The combined CYR61/RGS5 expression scores significantly correlated with the relapse-free-survival of EOC patients and can be used as predictors of EOC recurrence. Our study provides insights into the mechanism of EOC recurrence and presents CYR61+ relapse-initiating cells as potential therapeutic targets to prevent EOC relapse.
引用
收藏
页码:895 / 906
页数:11
相关论文
共 212 条
  • [41] Weinberg RA(2014)Systematic identification of signaling pathways with potential to confer anticancer drug resistance Sci Signal 7 ra121-14
  • [42] Dongre A(2003)Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies Br J Cancer 89 S23-87
  • [43] Weinberg RA(2016)Carcinoma-associated fibroblasts: orchestrating the composition of malignancy Genes Dev 30 1002-8
  • [44] Calon A(2007)Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer J Clin Pathol 60 1112-7
  • [45] Tauriello DV(2019)Inhibition of CYR61-S100A4 Axis Limits Breast Cancer Invasion Front Oncol 9 1074-9
  • [46] Batlle E(2001)Cyr61, a member of CCN family, is a tumor suppressor in non-small cell lung cancer J Biol Chem 276 47709-undefined
  • [47] Kan T(2012)A novel anti-Cyr61 antibody inhibits breast cancer growth and metastasis in vivo Cancer Immunol Immunother 61 677-undefined
  • [48] Wang W(2018)Targeting cysteine-rich angiogenic inducer-61 by antibody immunotherapy suppresses growth and migration of non-small cell lung cancer Exp Ther Med 16 730-undefined
  • [49] Ip PP(2010)MicroRNA-155 contributes to preeclampsia by down-regulating CYR61 Am J Obstet Gynecol 202 466.e1-undefined
  • [50] Zhou S(2005)Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression Nat Rev Cancer 5 744-undefined